Bayer/Onyx, Pfizer Submit NDAs For Fast-Track Kidney Cancer Agents
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer and Onyx expect to launch their renal cell carcinoma therapy BAY 43-9006 (sorafenib) in the first half of 2006